Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking
MedCity News
JANUARY 28, 2024
The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.
Let's personalize your content